{
  "docId": "019de073-7087-77cd-a846-97dda09bac98",
  "docSlug": "031593eaf739f40f0f0c49214c912ed3",
  "documentTitle": "9 Meters Biopharma | Investor Presentation Deck | 30 slides",
  "authorId": "9-meters-biopharma",
  "authorName": "9 Meters Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 30,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7087-77cd-a846-97dda09bac98/4",
  "deckHref": "/decks/019de073-7087-77cd-a846-97dda09bac98",
  "deckJsonHref": "/decks/019de073-7087-77cd-a846-97dda09bac98.json",
  "deckAnchorHref": "/decks/019de073-7087-77cd-a846-97dda09bac98#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.82,
        "y": 0.9
      },
      "kind": "image",
      "text": "9METERS BIOPHARMA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d33e10dc-aa23-47b4-a68f-5dba349ac587",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.48,
        "y": 0.64
      },
      "kind": "list",
      "text": "Leading institutional investor support and coverage by leading health care analysts. Nasdaq listed: NMTR. Cash runway through 4Q 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b08ac6b-5bb8-4b1d-9fbd-ffc97db21f75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.48,
        "y": 0.4
      },
      "kind": "list",
      "text": "Straightforward strategy: Employing capital-efficient development and commercialization pathways",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97cab409-a6a9-424a-9f72-5bc24fe02705",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.077,
        "y": 0.4
      },
      "kind": "list",
      "text": "Phase 3 clinical program: Vurolenatide - proprietary long-acting GLP-1 agonist for short bowel syndrome with plans to initiate Phase 3 study as early as 4Q",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca4570f8-a3a5-417d-8cb2-29a4d65b65bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.077,
        "y": 0.64
      },
      "kind": "list",
      "text": "Robust pipeline: Promising pipeline addressing unmet needs in GI diseases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e03735ef-a75b-45ab-85fe-6d776b6199b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.077,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Clinical stage company pioneering novel treatments for people with rare or debilitating digestive diseases",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12710754-5639-4596-b5fd-ce3b039db035",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.235,
        "x": 0.077,
        "y": 0.125
      },
      "kind": "title",
      "text": "Investor highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43c024f3-3561-4f17-aa92-b683b0a87983",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "3ab0a8d2-f595-4e86-99e5-0fe0b385fdb7",
      "evidence": "The slide is titled 'Investor highlights' and provides a summary of key points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 4,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f0bb03b9-dbca-4a94-92b4-3cb10f8828e5",
      "evidence": "Slides 3-4 use the Golden Circle framework",
      "position": 1,
      "objective": "Why 9 Meters Biopharma?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}